Skip to Main Content

Author Details

Jonathan Chou
University of California san francisco
2005
47
22
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36351060Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.Cancer Res2023
37922930Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.Lancet Oncol2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37316414Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.Clin Genitourin Cancer2023
37091148Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancer.Front Oncol2023
36648492Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.Clin Cancer Res2023
36435709Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.Urol Oncol2023
34998700Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.Clin Genitourin Cancer2022
36273492Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.Cancer Res2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35321431APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.Front Oncol2022
35216942TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.Eur Urol Oncol2022
34882781Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.Cancer2022
33293372Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.Clin Cancer Res2021
33840559Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.Eur Urol2021
33690902Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.Cancer2021
34108177Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.Clin Cancer Res2021
34326322An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.Nat Commun2021
33980590<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.J Immunother Cancer2021
33152701Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.J Natl Compr Canc Netw2020
31640893Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Eur Urol2020
32071145Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.Cancer Discov2020
31266829DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.Clin Cancer Res2019
31727800MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy.Life Sci Alliance2019
29339479HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice.Proc Natl Acad Sci U S A2018
29911109Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.Ann Transl Med2018
29906450Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.Cell2018
30033370Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
30340047Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
28581515GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.Oncogene2017
27019877Electrocardiography Evolution in a Woman Presenting With Alcohol Withdrawal Seizures and Cocaine Use.JAMA Intern Med2016
27559706Respiratory Failure in a Woman 8 Months After an Allogeneic Stem Cell Transplant.JAMA Oncol2016
27227311Metalloproteinases: a Functional Pathway for Myeloid Cells.Microbiol Spectr2016
25538248The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion.J Biol Chem2015
25415508Remodelling the extracellular matrix in development and disease.Nat Rev Mol Cell Biol2014
23354167GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.Nat Cell Biol2013
24036551microRNA-mediated regulation of the tumor microenvironment.Cell Cycle2013
22728437The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.Cancer Discov2012
23230184MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment.Cancer Discov2012
21317240Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization.Genes Dev2011
19798694GATA3 in development and cancer differentiation: cells GATA have it!J Cell Physiol2010
19487694EHD4 and CDH23 are interacting partners in cochlear hair cells.J Biol Chem2009
19741128Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers.J Neurosci2009
18667156Cocaine but not natural reward self-administration nor passive cocaine infusion produces persistent LTP in the VTA.Neuron2008
18719114Nucleus accumbens AGS3 expression drives ethanol seeking through G betagamma.Proc Natl Acad Sci U S A2008
17764007Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.Psychopharmacology (Berl)2007
16183644Three-dimensional solution structures of the chromodomains of cpSRP43.J Biol Chem2005
  • 1 - 47 of 47

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 8
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 15
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 5
Tuo Zhang
Weill Cornell Medical College.
Career Start Year 2013
Number of shared co-authors 3
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 1
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 4
Sungyong You
Cedars-Sinai Medical Center
Career Start Year 2008
Number of shared co-authors 16
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 21
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Bishoy M Faltas
Sandra and Edward Meyer Cancer Center
Career Start Year 2007
Number of shared co-authors 5
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Career Start Year 2005
Number of shared co-authors 23
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 3
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 10
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 26
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 6
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 13
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Dongquan Chen
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 0
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 2
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 0
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 9
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 8

Collaborators

Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 19
Eric J Small
University of California san francisco
Co-authored papers 15
Rahul Aggarwal
University of California San Francisco
Co-authored papers 12
Lawrence Fong
University of California san francisco
Co-authored papers 8
David A Quigley
University of California-San Francisco
Co-authored papers 8
Martin Sj??str??m
University of California-San Francisco
Co-authored papers 6
Alexander W Wyatt
University of British Columbia
Co-authored papers 6
Kim N Chi
University of British Columbia
Co-authored papers 6
Luke A Gilbert
Arc Institute
Co-authored papers 5
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 5
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Co-authored papers 5
Rohit Bose
Helen Diller Family Cancer Center, University of California San Francisco
Co-authored papers 5
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 4
Adam Foye
University of California San Francisco
Co-authored papers 4
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 4
Haolong Li
University of California san francisco
Co-authored papers 4
Christopher P Evans
University of California Davis
Co-authored papers 4
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 4
Primo N Lara
University of California Davis Comprehensive Cancer Center
Co-authored papers 4
Marcin Cieslik
Co-authored papers 4
Owen N Witte
University of California los angeles
Co-authored papers 4
Martin E Gleave
University of British Columbia
Co-authored papers 4
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 4
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 4
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 4
Raunak Shrestha
University of California San Francisco
Co-authored papers 3
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 3
Paul Lloyd
Bluestar Genomics Inc.
Co-authored papers 3
Thomas J George
UF Health Cancer Center
Co-authored papers 3
Release 1.2